Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity

References

• Perry VH, Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol. 2013;35(5):601–612.
   PubMed Web of Science ®Google Scholar
• Castren E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017;22(8):1085–1095.
   PubMed Web of Science ®Google Scholar
• Melzack R. From the gate to the neuromatrix. Pain. 1999;Suppl 6:S121–126. DOI:https://doi.org/10.1016/S0304-3959(99)00145-1.
   Google Scholar
• IASP terminology: international association for the study of pain. 2020. [cited 2020 Sep 10]. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698
   Google Scholar
• Trouvin AP, Perrot S. New concepts of pain. Best Pract Res Clin Rheumatol. 2019;33(3):101415.
   PubMed Web of Science ®Google Scholar
• von Hehn CA, Baron R, Woolf CJ, et al. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638–652.
   PubMed Web of Science ®Google Scholar
• Kim DS, Choi JO, Rim HD, et al. Downregulation of voltage-gated potassium channel alpha gene expression in dorsal root ganglia following chronic constriction injury of the rat sciatic nerve. Brain Res Mol Brain Res. 2002;105(1–2):146–152.
   PubMedGoogle Scholar
• Yam MF, Loh YC, Tan CS, et al. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci. 2018;19(8). DOI:https://doi.org/10.3390/ijms19082164.
   Web of Science ®Google Scholar
• Baldwin KT, Eroglu C. Molecular mechanisms of astrocyte-induced synaptogenesis. Curr Opin Neurobiol. 2017;45:113–120.
   PubMed Web of Science ®Google Scholar
• Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008;33(1):18–41.
   PubMed Web of Science ®Google Scholar
• Ji RR, Suter MR. P38 mapk, microglial signaling, and neuropathic pain. Mol Pain. 2007;3:33.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3312–3325.
   PubMed Web of Science ®Google Scholar
• Varrassi G, Fusco M, Coaccioli S, et al. Chronic pain and neurodegenerative processes in elderly people. Pain Pract. 2015;15(1): 1–3.
   PubMed Web of Science ®Google Scholar
• Fusco M, Skaper SD, Coaccioli S, et al. Degenerative joint diseases and neuroinflammation. Pain Pract. 2017;17(4): 522–532.
   PubMed Web of Science ®Google Scholar
• Boche D, Perry VH, Nicoll JA, et al. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol. 2013;39(1):3–18.
   PubMed Web of Science ®Google Scholar
• Varrassi G, Fusco M, Skaper SD, et al. A pharmacological rationale to reduce the incidence of opioid induced tolerance and hyperalgesia: a review. Pain Ther. 2018;7(1): 59–75.
   PubMed Web of Science ®Google Scholar
• Xie F, Zhang JC, Fu H, et al. Age-related decline of myelin proteins is highly correlated with activation of astrocytes and microglia in the rat cns. Int J Mol Med. 2013;32(5):1021–1028.
   PubMed Web of Science ®Google Scholar
• Biggs JE, Lu VB, Stebbing MJ, et al. Is bdnf sufficient for information transfer between microglia and dorsal horn neurons during the onset of central sensitization?. Mol Pain. 2010;6(44). DOI:https://doi.org/10.1186/1744-8069-6-44.
   Google Scholar
• Raghavendra V, Tanga F, DeLeo JA, et al. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306(2):624–630.
   PubMed Web of Science ®Google Scholar
• Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev. 2009;89(2):707–758.
   PubMed Web of Science ®Google Scholar
• Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the p2x7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114(3):386–396.
   PubMed Web of Science ®Google Scholar
• Bushong EA, Martone ME, Jones YZ, et al. Protoplasmic astrocytes in ca1 stratum radiatum occupy separate anatomical domains. J Neurosci. 2002;22(1):183–192.
   PubMed Web of Science ®Google Scholar
• Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. Trends Neurosci. 2013;36(9):513–521.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Giusti P, Facci L, et al. Microglia and mast cells: two tracks on the road to neuroinflammation. Faseb J. 2012;26(8): 3103–3117.
   PubMed Web of Science ®Google Scholar
• Héron A, Dubayle D. A focus on mast cells and pain. J Neuroimmunol. 2013;264(1–2):1–7.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Kawakita K, Kiso Y, et al. Substance p induces granulocyte infiltration through degranulation of mast cells. J Immunol. 1989;142(3):927–931.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Perkins NM, Tracey DJ, et al. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain. 2003;105(3):467–479.
   PubMed Web of Science ®Google Scholar
• Mika J, Zychowska M, Popiolek-Barczyk K, et al. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013;716(1–3):106–119.
   PubMed Web of Science ®Google Scholar
• Alfonso Romero-Sandoval E, Sweitzer S. Nonneuronal central mechanisms of pain: glia and immune response. Prog Mol Biol Transl Sci. 2015;131:325–358.
   PubMed Web of Science ®Google Scholar
• Rajchgot T, Thomas SC, Wang JC, et al. Neurons and microglia; a sickly-sweet duo in diabetic pain neuropathy. Front Neurosci. 2019;13:25.
   PubMed Web of Science ®Google Scholar
• Liampas A, Rekatsina M, Vadalouca A, et al. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021;10(1):55-68.
   Web of Science ®Google Scholar
• Zhuang ZY, Wen YR, Zhang DR, et al. A peptide c-jun n-terminal kinase (jnk) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of jnk activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci. 2006;26(13):3551–3560.
   PubMed Web of Science ®Google Scholar
• Zhang J, De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem. 2006;97(3):772–783.
   PubMed Web of Science ®Google Scholar
• Deogracias R, Yazdani M, Dekkers MP, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases bdnf levels and improves symptoms of a mouse model of rett syndrome. Proc Natl Acad Sci U S A. 2012;109(35):14230–14235.
   PubMed Web of Science ®Google Scholar
• Ferrini F, Salio C, Boggio E, et al. Interplay of bdnf and gdnf in the mature spinal somatosensory system and its potential therapeutic relevance. Curr Neuropharmacol. 2020 Nov 16. doi: https://doi.org/10.2174/1570159X18666201116143422.
   Google Scholar
• Smith PA. Bdnf: no gain without pain?. Neuroscience. 2014;283:107–123.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Johnson EM Jr. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned?. Neurobiol Dis. 2017;97(Pt B):156–168.
   PubMedGoogle Scholar
• Nibuya M, Morinobu S, Duman RS, et al. Regulation of bdnf and trkb mrna in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15(11):7539–7547.
   PubMed Web of Science ®Google Scholar
• Castrén E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017;22(8):1085–1095.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389–399.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM, et al. Calcitonin gene-related peptide (cgrp) and migraine current understanding and state of development. Headache. 2013;53(8):1230–1244.
   PubMed Web of Science ®Google Scholar
• Yeh J-F, Akinci A, Al Shaker M, et al. Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications. Mol Pain. 2017;13:1744806917740233.
   Web of Science ®Google Scholar
• Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA, et al. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology. 2008;108(4):722–734.
   PubMed Web of Science ®Google Scholar
• Alkaitis MS, Solorzano C, Landry RP, et al. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One. 2010;5(5): e10891.
   PubMed Web of Science ®Google Scholar
• Speth C, Dierich MP, Gasque P, et al. Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol. 2002;38(9):669–679.
   PubMed Web of Science ®Google Scholar
• Le Friec G, Kemper C. Complement: coming full circle. Arch Immunol Ther Exp (Warsz). 2009;57(6):393–407.
   PubMed Web of Science ®Google Scholar
• Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today. 1996;17(10):461–466.
   PubMedGoogle Scholar
• West EE, Kolev M, Kemper C, et al. Complement and the regulation of t cell responses. Annu Rev Immunol. 2018;36(1):309–338.
   PubMedGoogle Scholar
• Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep. 2008;60(3):297–307.
   PubMed Web of Science ®Google Scholar
• Strand V, Burmester GR, Ogale S, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled radiate study. Rheumatology (Oxford). 2012;51(10):1860–1869.
   PubMed Web of Science ®Google Scholar
• Scholz J, Abele A, Marian C, et al. Low-dose methotrexate reduces peripheral nerve injury-evoked spinal microglial activation and neuropathic pain behavior in rats. Pain. 2008;138(1):130–142.
   PubMed Web of Science ®Google Scholar
• Kersten C, Cameron MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep. 2012;2012:bcr1220115374.
   Google Scholar
• Kersten C, Cameron MG, Laird B, et al. Epidermal growth factor receptor-inhibition (egfr-i) in the treatment of neuropathic pain. Br J Anaesth. 2015;115(5):761–767.
   PubMed Web of Science ®Google Scholar
• Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and egfr interactions are involved in pain processing. J Clin Invest. 2017;127(9):3353–3366.
   PubMed Web of Science ®Google Scholar
• Christidis N, Kang I, Cairns BE, et al. Expression of 5-ht3 receptors and ttx resistant sodium channels (na(v)1.8) on muscle nerve fibers in pain-free humans and patients with chronic myofascial temporomandibular disorders. J Headache Pain. 2014;15(1):63.
   PubMedGoogle Scholar
• Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014;66(3):676–814.
   PubMed Web of Science ®Google Scholar
• Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120(6):1315–1334.
   PubMed Web of Science ®Google Scholar
• Waszkielewicz AM, Gunia A, Szkaradek N, et al. Ion channels as drug targets in central nervous system disorders. Curr Med Chem. 2013;20(10):1241–1285.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Sanacora G, Duman RS, et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66(1): 509–523.
   PubMed Web of Science ®Google Scholar
• Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238–249.
   PubMed Web of Science ®Google Scholar
• Corasaniti MT, Amantea D, Russo R, et al. The crucial role of neuronal plasticity in pain and cell death. Cell Death & Differentiation. 2006;13(3):534–536.
   PubMedGoogle Scholar
• Tencheva A, Liu R, Volkova TV, et al. Synthetic analogues of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies. Amino Acids. 2020;52(11–12):1559–1580.
   PubMed Web of Science ®Google Scholar
• Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361–1368.
   PubMed Web of Science ®Google Scholar
• Patel RN, Attur MG, Dave MN, et al. A novel mechanism of action of chemically modified tetracyclines: inhibition of cox-2-mediated prostaglandin e2 production. J Immunol. 1999;163(6):3459–3467.
   PubMed Web of Science ®Google Scholar
• Ismail CAN, Suppian R, Aziz CBA, et al. Minocycline attenuates the development of diabetic neuropathy by modulating dream and bdnf protein expression in rat spinal cord. J Diabetes Metab Disord. 2019;18(1):181–190.
   PubMed Web of Science ®Google Scholar
• Jin SX, Zhuang ZY, Woolf CJ, et al. P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23(10):4017–4022.
   PubMed Web of Science ®Google Scholar
• Patel MK, Kaye AD, Urman RD, et al. Tanezumab: therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34(1):111–116.
   PubMed Web of Science ®Google Scholar
• Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16(6):1163–1176.
   PubMed Web of Science ®Google Scholar
• Chang DS, Hsu E, Hottinger DG, et al. Anti-nerve growth factor in pain management: current evidence. J Pain Res. 2016;9:373–383.
   PubMed Web of Science ®Google Scholar
• Watson JJ, Allen SJ, Dawbarn D, et al. Targeting nerve growth factor in pain: what is the therapeutic potential?. BioDrugs. 2008;22(6):349–359.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (ngf) for pain management: what does the future hold for ngf antagonists?. Drugs. 2014;74(6):619–626.
   PubMed Web of Science ®Google Scholar
• Kan SL, Li Y, Ning GZ, et al. Tanezumab for patients with osteoarthritis of the knee: a meta-analysis. PLoS One. 2016;11(6):e0157105.
   PubMed Web of Science ®Google Scholar
• Chen J, Li J, Li R, et al. Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med. 2017;18(2):374–385.
   PubMed Web of Science ®Google Scholar
• Webb MP, Helander EM, Menard BL, et al. Tanezumab: a selective humanized mab for chronic lower back pain. Ther Clin Risk Manag. 2018;14:361–367.
   PubMed Web of Science ®Google Scholar
• P2y12 nucleotide receptor antagonioss, including clopidogrel, for the treatment of stroke. Global Summit on Stroke, Birmingham, UK, 2015. https://www.longdom.org/proceedings/p2y12-nucleotide-receptor-antagonists-including-clopidogrel-for-the-treatment-of-stroke-16555.html
   Google Scholar
• Neumann A, Müller CE, Namasivayam V, et al. P2y1-like nucleotide receptors—structures, molecular modeling, mutagenesis, and oligomerization. Wiley Interdiscip Rev Comput Mol Sci. 2020;10(4):e1464.
   Web of Science ®Google Scholar
• Inoue K. Atp receptors of microglia involved in pain. Novartis Found Symp. 2006;276: 263–272. discussion 273-281.
   PubMedGoogle Scholar
• Watkins LR, Hutchinson MR, Rice KC, et al. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30(11):581–591.
   PubMed Web of Science ®Google Scholar
• Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology. 2008;54(1):16–22.
   PubMed Web of Science ®Google Scholar
• Esposito E, Paterniti I, Mazzon E, et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun. 2011;25(6):1099–1112.
   PubMed Web of Science ®Google Scholar
• Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15–19.
   PubMed Web of Science ®Google Scholar
• Del Giorno R, Skaper S, Paladini A, et al. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015;4(2):169–178.
   PubMed Web of Science ®Google Scholar
• Smart D, Jonsson KO, Vandevoorde S, et al. ‘Entourage’ effects of n-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol. 2002;136(3):452–458.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Davis JB, Di Marzo V, et al. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid vr1 receptors. FEBS Lett. 2001;506(3):253–256.
   PubMed Web of Science ®Google Scholar
• Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther. 2002;302(3):839–845.
   PubMed Web of Science ®Google Scholar
• Cerrato S, Brazis P, della Valle MF, et al. Effects of palmitoylethanolamide on immunologically induced histamine, pgd2 and tnfalpha release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133(1):9–15.
   PubMed Web of Science ®Google Scholar
• Loría F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci. 2008;28(4):633–641.
   PubMed Web of Science ®Google Scholar
• Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther. 2008;326(1):12–23.
   PubMed Web of Science ®Google Scholar
• Costa B, Conti S, Giagnoni G, et al. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137(4):413–420.
   PubMed Web of Science ®Google Scholar
• Calignano A, La Rana G, Piomelli D, et al. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001;419(2–3):191–198.
   PubMed Web of Science ®Google Scholar
• Mazzari S, Canella R, Petrelli L, et al. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996;300(3):227–236.
   PubMed Web of Science ®Google Scholar
• Paladini A, Varrassi G, Bentivegna G, et al. Palmitoylethanolamide in the treatment of failed back surgery syndrome. Pain Res Treat. 2017;2017:1486010.
   PubMed Web of Science ®Google Scholar
• Scaturro D, Asaro C, Lauricella L, et al. Combination of rehabilitative therapy with ultramicronized palmitoylethanolamide for chronic low back pain: an observational study. Pain Ther. 2020;9(1):319–326.
   PubMed Web of Science ®Google Scholar
• Paladini A, Fusco M, Cenacchi T, et al. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11–24.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Kurotani T, Komatsu Y, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404–411.
   PubMed Web of Science ®Google Scholar
• Kawasaki A, Hoshino K, Osaki R, et al. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma. 1992;29(4):245–252.
   PubMed Web of Science ®Google Scholar
• Liu J, Feng X, Yu M, et al. Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett. 2007;412(3):268–272.
   PubMed Web of Science ®Google Scholar
• Lundblad R, Ekstrøm P, Giercksky KE, et al. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock. 1995;3(3):210–215.
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Tanga F, Rutkowski MD, et al. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain. 2003;104(3):655–664.
   PubMed Web of Science ®Google Scholar
• Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, et al. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun. 2007;21(2):238–246.
   PubMed Web of Science ®Google Scholar
• Frampton M, Harvey RJ, Kirchner V, et al. Propentofylline for dementia. Cochrane Database Syst Rev. 2003;2:Cd002853.
   PubMedGoogle Scholar
• Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008;5(12):16–19.
   PubMedGoogle Scholar
• Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des. 2005;11(23):2945–2960.
   PubMed Web of Science ®Google Scholar
• Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008;320(5874):385–388.
   PubMed Web of Science ®Google Scholar
• Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (flame): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–130.
   PubMed Web of Science ®Google Scholar
• Squillace S, Spiegel S, Salvemini D, et al. Targeting the sphingosine-1-phosphate axis for developing non-narcotic pain therapeutics. Trends Pharmacol Sci. 2020;41(11):851–867.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration: fda expands approval of gilenya to treat multiple sclerosis in pediatric patients. Rockville, Maryland: Food and Drug Administration; 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gilenya-treat-multiple-sclerosis-pediatric-patients
   Google Scholar
• Leung L, Cahill CM. Tnf-alpha and neuropathic pain–a review. J Neuroinflammation. 2010;7:27.
   PubMed Web of Science ®Google Scholar
• Hess A, Axmann R, Rech J, et al. Blockade of tnf-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011;108(9):3731–3736.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. Jama. 2019;322(1):37–48.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Fornasari D, Pergolizzi J, et al. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21(7):1672–1683.
   PubMed Web of Science ®Google Scholar
• Kucyi A, Davis KD. The neural code for pain: from single-cell electrophysiology to the dynamic pain connectome. Neuroscientist. 2017;23(4):397–414.
   PubMed Web of Science ®Google Scholar
• Kucyi A, Davis KD. The dynamic pain connectome. Trends Neurosci. 2015;38(2):86–95.
   PubMed Web of Science ®Google Scholar
• Costigan M, Scholz J, Woolf CJ, et al. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32(1):1–32.
   PubMed Web of Science ®Google Scholar